AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37304207 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 37304432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FLV) treatment for 2 months
Number of subjects: 65
Study 37304498 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Care Approach (DCA)
Number of subjects: 3211
Study 37304498 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 3211
Study 37304498 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA
Number of subjects: 3211
Study 37304498 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 3211
Study 37304494 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI + DRV/r (Dolutegravir or Elvitegravir)
Number of subjects: 318
Study 37304494 — intervention group
Group type: COMPARATOR
Intervention: SOC (2NRTI + boosted PI/NNRTI)
Number of subjects: 318
Study 37304494 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI + DRV/r
Number of subjects: 318
Study 37304494 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 318
Study 37304846 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron and folic acid (WIFA) supplementation and menstrual hygiene management (MHM) support for girls
Number of subjects: 2244
Study 37304846 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change interventions to improve nutrition, MHM, and WASH knowledge
Number of subjects: 2244
Study 37304846 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey assessing nutrition, MHM, and WASH knowledge and experience
Number of subjects: 2244
Study 37304846 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient status measurement
Number of subjects: 2244
Study 37304846 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH infrastructure observation
Number of subjects: 2244
Study 37305080 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch thickened formula with reduced lactose content, probiotics and prebiotics, administered for 30 days.
Number of subjects: 101
Study 37305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal preconception BMI and gestational weight gain (CGWG)
Number of subjects: 864
Study 37305082 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal conditional GWG (CGWG)
Number of subjects: 864
Study 37305429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride and metformin hydrochloride
Number of subjects: 120
Study 37305429 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride
Number of subjects: 120
Study 37305610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led decision counseling program plus usual care
Number of subjects: 20
Study 37305610 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 20
Study 37306039 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 1-3 months of DAPT
Number of subjects: 0
Study 37306039 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 37306107 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg orally on Days 1-21 and ganitumab 18 mg/kg intravenously on Days 1 and 15 of a 28-day cycle.
Number of subjects: 10
Study 37306107 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg daily for 21 days (after dose reduction due to DLTs).
Number of subjects: 10
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation at private pharmacies
Number of subjects: 287
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP continuation at 1 month
Number of subjects: 287
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP continuation at 4 months
Number of subjects: 287
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP continuation at 7 months
Number of subjects: 287
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill coverage
Number of subjects: 287
Study 37306128 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of pharmacy-delivered PrEP services
Number of subjects: 287
Study 37306288 — intervention group
Group type: COMPARATOR
Intervention: BAY1128688 (3, 30, or 90 mg once daily or 60 mg twice daily for 14 days)
Number of subjects: 51
Study 37306288 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 (60 mg once or twice daily for 28 days)
Number of subjects: 51
Study 37306288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 37306407 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOS stent
Number of subjects: 3060
Study 37306430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-PFMT
Number of subjects: 45
Study 37306430 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-PFMT
Number of subjects: 45
Study 37306430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 37306636 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin-only Manchester Acute Coronary Syndromes decision aid
Number of subjects: 817
Study 37306636 — intervention group
Group type: EXPERIMENTAL
Intervention: History, ECG, Age, Risk Factors, Troponin
Number of subjects: 817
Study 37306636 — intervention group
Group type: EXPERIMENTAL
Intervention: History and ECG-only Manchester Acute Coronary Syndromes decision aid
Number of subjects: 817
Study 37306636 — intervention group
Group type: EXPERIMENTAL
Intervention: History, ECG, Age, Risk Factors
Number of subjects: 817
Study 37306637 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated HEART score less or equal to 3
Number of subjects: 3752
Study 37306637 — intervention group
Group type: COMPARATOR
Intervention: Original HEART score less or equal to 3
Number of subjects: 3752
Study 37306637 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated TIMI score less or equal to 1
Number of subjects: 3752
Study 37306637 — intervention group
Group type: COMPARATOR
Intervention: Original TIMI score less or equal to 1
Number of subjects: 3752
Study 37306637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonischemic ECG with hs-cTn T less than LOD/LOQ
Number of subjects: 3752
Study 37306637 — intervention group
Group type: COMPARATOR
Intervention: Nonischemic ECG with hs-cTn T below the 99th percentile
Number of subjects: 3752
Study 37306717 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan (CCX168)
Number of subjects: 1
Study 37306717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 37306720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-medium adherence (80-100%)
Number of subjects: 18
Study 37306720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherence (0-79%)
Number of subjects: 18
Study 37306763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping
Number of subjects: 17
Study 37306813 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
Number of subjects: 21
Study 37306874 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (integrated treatment for gambling and PTSD)
Number of subjects: 65
Study 37306874 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Pathological Gambling (for gambling alone)
Number of subjects: 65
Study 37306874 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 65
Study 37306874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 65
Study 37307001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg orally once a day for 12 weeks
Number of subjects: 134
Study 37307001 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once a day for 12 weeks
Number of subjects: 134
Study 37307001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 134
Study 37307001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 37307005 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on Rehmannia-6-based Chinese medicine treatment for 48 weeks
Number of subjects: 148
Study 37307005 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 148
Study 37307005 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on Rehmannia-6-based Chinese medicine treatment
Number of subjects: 148
Study 37307078 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAUS assessment tool
Number of subjects: 30
Study 37307078 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR assessment tool
Number of subjects: 30
Study 37307142 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute minimal examination time
Number of subjects: 1926
Study 37307142 — intervention group
Group type: COMPARATOR
Intervention: Baseline examination time
Number of subjects: 1926
Study 37307232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 μg kg -1 bolus followed by 0.4 μg kg -1 h -1 maintenance until dural closure)
Number of subjects: 252
Study 37307232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 252
Study 37307232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 252
Study 37307232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 37307310 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37307514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by Nivolumab 3 mg/kg once every 2 weeks for ≤24 months
Number of subjects: 533
Study 37307514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab followed by Nivolumab monotherapy
Number of subjects: 533
Study 37307519 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 2806
Study 37307519 — intervention group
Group type: EXPERIMENTAL
Intervention: Village Health Clubs (VHC)
Number of subjects: 2806
Study 37307519 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2806
Study 37307528 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliprotect (5 times a day for the initial 2 weeks and on demand thereafter)
Number of subjects: 275
Study 37307528 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg q.d.)
Number of subjects: 275
Study 37307537 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based feedback
Number of subjects: 22
Study 37307537 — intervention group
Group type: COMPARATOR
Intervention: Conventional feedback
Number of subjects: 22
Study 37307902 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light imaging (BLI)
Number of subjects: 901
Study 37307902 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 901
Study 37307902 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 901
Study 37308042 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site training arm (TRA)
Number of subjects: 1158
Study 37308042 — intervention group
Group type: COMPARATOR
Intervention: No on-site training arm (NO-TRA)
Number of subjects: 1158
Study 37308042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1158
Study 37308076 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based blood pressure management supported by community blood pressure monitors and a mobile health application (CBPM arm)
Number of subjects: 0
Study 37308076 — intervention group
Group type: EXPERIMENTAL
Intervention: An identical strategy to the CBPM arm using a cellular blood pressure cuff (eCBPM+ arm)
Number of subjects: 0
Study 37308076 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC arm) clinic-based management
Number of subjects: 0
Study 37308076 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 0
Study 37308133 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (C1 group)
Number of subjects: 55
Study 37308133 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (C2 group)
Number of subjects: 55
Study 37308218 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once a day
Number of subjects: 3209
Study 37308218 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week with concomitant methotrexate (MTX)
Number of subjects: 3209
Study 37308218 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 3209
Study 37308251 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-2 sublingual tablet
Number of subjects: 914
Study 37308251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study 37308268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 300
Study 37308268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 37308285 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular shift surgery
Number of subjects: 68
Study 37308285 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic arthroscopy alone
Number of subjects: 68
Study 37308342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg daily
Number of subjects: 83
Study 37308396 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA level at diagnosis ≥ or <30 ng/mL and presence or not of KRAS-mutated ctDNA at D28
Number of subjects: 65
Study 37308396 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA level at diagnosis and presence of KRAS-mutated ctDNA at D28
Number of subjects: 65
Study 37308490 — intervention group
Group type: EXPERIMENTAL
Intervention: JMT101 plus osimertinib 160 mg
Number of subjects: 121
Study 37308679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for SUD
Number of subjects: 76
Study 37308751 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of once-weekly insulin icodec
Number of subjects: 163
Study 37308751 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dose of once-weekly insulin icodec
Number of subjects: 163
Study 37308751 — intervention group
Group type: COMPARATOR
Intervention: Double dose of once-daily insulin glargine U100
Number of subjects: 163
Study 37308751 — intervention group
Group type: COMPARATOR
Intervention: Triple dose of once-daily insulin glargine U100
Number of subjects: 163
Study 37308751 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 163
Study 37308751 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 163
Study 37308874 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with PD
Number of subjects: 20
Study 37308874 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched persons without PD)
Number of subjects: 20
Study 37308905 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid infusion group (Ringer's lactate solution, maintaining PPV within 6-9%)
Number of subjects: 97
Study 37308905 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid infusion group (maintaining PPV within 13-16%)
Number of subjects: 97
Study 37308905 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 97
Study 37308969 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMF treatment and eccentric exercise
Number of subjects: 40
Study 37308969 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment and eccentric exercise
Number of subjects: 40
Study 37308971 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab (1000 mg weekly intravenous infusion) with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Number of subjects: 101
Study 37308971 — intervention group
Group type: COMPARATOR
Intervention: Placebo with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Number of subjects: 101
Study 37309006 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) for 12 weeks
Number of subjects: 336
Study 37309006 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation program (Ending Self-Stigma) for 12 weeks
Number of subjects: 336
Study 37309006 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 336
Study 37309006 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT)
Number of subjects: 336
Study 37309006 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation program (Ending Self-Stigma)
Number of subjects: 336
Study 37309193 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (DW1903) daily for 2 weeks
Number of subjects: 476
Study 37309193 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg (DW1903R1) daily for 2 weeks
Number of subjects: 476
Study 37309249 — intervention group
Group type: EXPERIMENTAL
Intervention: Belly roll (Bero) protein
Number of subjects: 0
Study 37309249 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37309365 — intervention group
Group type: EXPERIMENTAL
Intervention: Octocog alfa (BAY 81-8973) prophylaxis
Number of subjects: 113
Study 37309365 — intervention group
Group type: COMPARATOR
Intervention: rFVIII-FS prophylaxis
Number of subjects: 113
Study 37309696 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) defined as serum ferritin < 100 μg/L or ferritin 100-299 μg/L with transferrin saturation < 20%.
Number of subjects: 461
Study 37309696 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine laboratory examinations for diagnosing ID.
Number of subjects: 461
Study 37309702 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib (COMBO)
Number of subjects: 0
Study 37309702 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (VEMU)
Number of subjects: 0
Study 37309702 — intervention group
Group type: COMPARATOR
Intervention: Encorafenib (ENCO)
Number of subjects: 0
Study 37309702 — intervention group
Group type: COMPARATOR
Intervention: COMBO, VEMU, ENCO
Number of subjects: 0
Study 37309702 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO
Number of subjects: 0
Study 37310015 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic enhanced-view totally extraperitoneal (eTEP)
Number of subjects: 100
Study 37310015 — intervention group
Group type: COMPARATOR
Intervention: Robotic intraperitoneal onlay mesh (rIPOM)
Number of subjects: 100
Study 37310119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendrimer PET tracer
Number of subjects: 0
Study 37310167 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 266
Study 37310167 — intervention group
Group type: COMPARATOR
Intervention: Radical resection (RR)
Number of subjects: 266
Study 37310174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 159
Study 37310174 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-Mask Continuous Positive Airway Pressure (CPAP)
Number of subjects: 159
Study 37310174 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet Continuous Positive Airway Pressure (CPAP)
Number of subjects: 159
Study 37310224 — intervention group
Group type: EXPERIMENTAL
Intervention: INLAIs (specifically BDM-2)
Number of subjects: 0
Study 37310224 — intervention group
Group type: EXPERIMENTAL
Intervention: BDM-2
Number of subjects: 0
Study 37310243 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate post-CCTA management
Number of subjects: 14232
Study 37310243 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate post-CCTA management
Number of subjects: 14232
Study 37310246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0
Study 37310246 — intervention group
Group type: COMPARATOR
Intervention: Dietary and exercise counseling (Control)
Number of subjects: 0
Study 37310308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 37310308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (AVP)
Number of subjects: 0
Study 37310308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37310306 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Transition (MT)
Number of subjects: 0
Study 37310306 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 37310329 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week CBT-I via a smartphone application
Number of subjects: 320
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on anti-CD20
Number of subjects: 90
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on fingolimod
Number of subjects: 90
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on other treatments
Number of subjects: 90
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed booster vaccination in MS patients on anti-CD20
Number of subjects: 90
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 primary and booster vaccination in MS patients on other treatments
Number of subjects: 90
Study 37310391 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination in MS patients on anti-CD20
Number of subjects: 90
Study 37310415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytochemicals from herbs/spices consumed in a meal
Number of subjects: 24
Study 37310492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 169
Study 37310492 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sham mindfulness
Number of subjects: 169
Study 37310492 — intervention group
Group type: EXPERIMENTAL
Intervention: General sham mindfulness
Number of subjects: 169
Study 37310492 — intervention group
Group type: COMPARATOR
Intervention: Audiobook control
Number of subjects: 169
Study 37310776 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive communication group
Number of subjects: 249
Study 37310776 — intervention group
Group type: COMPARATOR
Intervention: Negative communication (nocebo) group
Number of subjects: 249
Study 37310776 — intervention group
Group type: COMPARATOR
Intervention: Neutral communication (neutral) group
Number of subjects: 249
Study 37310781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided digital training (DT) course
Number of subjects: 262